---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Pharmacology questions"
description: "Pharmacology questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Ocrevus (ocrelizumab) work (mechanism of action)? How is Ocrevus (ocrelizumab) metabolized? What is the half-life of Ocrevus (ocrelizumab)? What are the inactive ingredients in Ocrevus and Ocrevus Zunovo? 2 further questions follow. 6 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Pharmacology questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications](https://www.evicenter.com/medical-information/ocrevus).

## Mechanism

<a id="ocrevus-mechanism"></a>

### How does Ocrevus (ocrelizumab) work (mechanism of action)?

> “The precise mechanisms through which OCREVUS [IV] and OCREVUS ZUNOVO exert their therapeutic clinical effects in relapsing multiple sclerosis (RMS) and relapsing-remitting multiple sclerosis (RRMS) are not fully elucidated but are presumed to involve immunomodulation through selective binding to CD20-expressing B cells. Following cell surface binding to B lymphocytes, OCREVUS [IV] and OCREVUS ZUNOVO result in antibody-dependent cellular cytolysis and complement-mediated lysis.<sup>1,3</sup>
>
> OCREVUS [IV] and OCREVUS ZUNOVO contain ocrelizumab, a recombinant humanized monoclonal antibody directed against CD20-expressing B cells. Lymphoid stem cells and plasma cells do not express CD20 and therefore are not directly targeted by OCREVUS [IV] or OCREVUS ZUNOVO.<sup>1,3,6</sup>”

Source: [OCREVUS: Why ocrelizumab, captured 2026-11-12](https://www.ocrevus-hcp.com/why-ocrelizumab.html#:~:text=The%20precise%20mechanisms%20through%20which,by%20OCREVUS%20%5BIV%5D%20or%20OCREVUS)

<a id="ocrevus-zunovo-same-as-iv"></a>

### Is Ocrevus Zunovo the same medicine as Ocrevus IV?

> “OCREVUS ZUNOVO and OCREVUS [IV] both contain the same active ingredient ocrelizumab<sup>1-3</sup>”

Source: [OCREVUS: Why ocrelizumab, captured 2026-11-12](https://www.ocrevus-hcp.com/why-ocrelizumab.html#:~:text=OCREVUS%20ZUNOVO%20and%20OCREVUS%20%5BIV%5D%20both%20contain%20the%20same%20active%20ingredient)

> “OCREVUS ZUNOVO and OCREVUS [IV] have the same mechanism of action<sup>1,3,6,9</sup>”

Source: [OCREVUS: Why ocrelizumab, captured 2026-11-12](https://www.ocrevus-hcp.com/why-ocrelizumab.html#:~:text=OCREVUS%20ZUNOVO%20and%20OCREVUS%20%5BIV%5D%20have%20the%20same%20mechanism%20of)

> “OCREVUS ZUNOVO also contains hyaluronidase, an active excipient that works in a transient and reversible way to increase the dispersion area and allow large fluid volumes to be administered subcutaneously.<sup>3,10,11</sup>”

Source: [OCREVUS: Why ocrelizumab, captured 2026-11-12](https://www.ocrevus-hcp.com/why-ocrelizumab.html#:~:text=OCREVUS%20ZUNOVO%20also%20contains%20hyaluronidase%2C,fluid%20volumes%20to%20be%20administered)

> “No clinically significant difference to OCREVUS<sup>®</sup> [IV] based on pharmacokinetic (PK) exposure<sup>1</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=No%20clinically%20significant%20difference%20to,%5BIV%5D%20based%20on%20pharmacokinetic%20%28PK%29)

> “Safety profile consistent with OCREVUS<sup>®</sup> [IV] with the exception of injection reactions<sup>1,2</sup>”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/safety.html#:~:text=Safety%20profile%20consistent%20with,with%20the%20exception%20of%20injection)

> “In Study 4, the differences in pharmacokinetic exposures following the administration of OCREVUS ZUNOVO 
> subcutaneously at 920 mg/23,000 units and ocrelizumab intravenously at 600 mg in MS patients were not 
> clinically significant.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 14, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=14)

> “The most common adverse reactions (reported in at least 10% of OCREVUS ZUNOVO-treated patients) were 
> injection reactions.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 11, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=11)

Note: Study 4 of the OCREVUS ZUNOVO Prescribing Information is OCARINA II.

<a id="ocrevus-b-cell-recovery"></a>

### How long after the last Ocrevus dose do B cells recover?

> “For B-cell counts, assays for CD19+ B-cells are used because the presence of ocrelizumab interferes with the 
> CD20 assay.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 14, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=14)

> “In clinical studies with OCREVUS ZUNOVO and intravenous ocrelizumab, CD19+ B-cell counts 
> in blood were reduced by 14 days after administration. In clinical studies with intravenous ocrelizumab, B-cell 
> counts rose to above the lower limit of normal (LLN) or above baseline counts between infusions of ocrelizumab 
> at least one time in 0.3% to 4.1% of patients. In a clinical study of 51 patients treated with intravenous 
> ocrelizumab, the median time for B-cell counts to return to either baseline or LLN was 72 weeks (range 27-175 
> weeks) after the last ocrelizumab infusion. Within 2.5 years after the last infusion, B-cell counts rose to either 
> baseline or LLN in 90% of patients.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 14, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=14)

## Pharmacokinetics

<a id="ocrevus-metabolism"></a>

### How is Ocrevus (ocrelizumab) metabolized?

> “Metabolism 
> The metabolism of OCREVUS has not been directly studied because antibodies are cleared principally by 
> catabolism.”

Source: [OCREVUS: OCREVUS \[IV\], page 17, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=17)

> “Metabolism 
> The metabolism of OCREVUS ZUNOVO has not been directly studied because antibodies are cleared principally 
> by catabolism.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 15, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=15)

Note: The first passage is from the OCREVUS (intravenous) Prescribing Information; the second is from the OCREVUS ZUNOVO Prescribing Information.

<a id="ocrevus-half-life"></a>

### What is the half-life of Ocrevus (ocrelizumab)?

> “Elimination  
> Constant clearance was estimated at 0.17 L/day, and initial time-dependent clearance at 0.05 L/day, which 
> declined with a half-life of 33 weeks. The terminal elimination half-life was 26 days.”

Source: [OCREVUS: OCREVUS \[IV\], page 17, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=17)

> “Elimination 
> Constant clearance was estimated at 0.17 L/day, and initial time-dependent clearance at 0.05 L/day, which 
> declined with a half-life of 33 weeks. The terminal elimination half-life was 20 days.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 15, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=15)

Note: The first passage is from the OCREVUS (intravenous) Prescribing Information; the second is from the OCREVUS ZUNOVO Prescribing Information.

## Components

<a id="ocrevus-inactive-ingredients"></a>

### What are the inactive ingredients in Ocrevus and Ocrevus Zunovo?

> “OCREVUS (ocrelizumab) injection for intravenous infusion is a preservative-free, sterile, clear or slightly 
> opalescent, and colorless to pale brown solution supplied in single-dose vials. Each mL of solution contains 30 
> mg ocrelizumab, glacial acetic acid (0.25 mg), polysorbate 20 (0.2 mg), sodium acetate trihydrate (2.14 mg), 
> and trehalose dihydrate (40 mg) at pH 5.3.”

Source: [OCREVUS: OCREVUS \[IV\], page 16, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=16)

> “OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq) injection for subcutaneous use is a sterile, 
> preservative-free, clear to slightly opalescent, and colorless to pale brown solution supplied in single-dose vials. 
> Each 23 mL of solution contains 920 mg ocrelizumab, 23,000 units of hyaluronidase (human recombinant), glacial 
> acetic acid (5.5 mg), methionine (34.3 mg), polysorbate 20 (13.8 mg), sodium acetate (30.2 mg), trehalose 
> (1889.5 mg), and water for injection at pH 5.3.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 14, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=14)

Note: Both passages are from the Description section of the Prescribing Information: the first for OCREVUS (intravenous), the second for OCREVUS ZUNOVO.

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply)
